Takeda Pharmaceutical (NYSE:TAK) Reaches New 52-Week Low at $13.04

Takeda Pharmaceutical Company Limited (NYSE:TAKGet Rating)’s stock price reached a new 52-week low during trading on Wednesday . The stock traded as low as $13.04 and last traded at $13.05, with a volume of 111472 shares traded. The stock had previously closed at $13.22.

Analyst Upgrades and Downgrades

Several equities analysts have commented on TAK shares. Jefferies Financial Group downgraded shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, July 29th. Cowen raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Tuesday, July 19th. Finally, Cowen raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $21.00 to $24.00 in a research report on Tuesday, July 19th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $24.00.

Takeda Pharmaceutical Trading Up 1.3 %

The company has a debt-to-equity ratio of 0.68, a current ratio of 1.18 and a quick ratio of 0.75. The company has a market capitalization of $40.81 billion, a price-to-earnings ratio of 24.83, a price-to-earnings-growth ratio of 0.53 and a beta of 0.70. The business’s 50 day simple moving average is $13.94 and its 200 day simple moving average is $14.22.

Takeda Pharmaceutical (NYSE:TAKGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.56 EPS for the quarter. The company had revenue of $7.51 billion for the quarter. Takeda Pharmaceutical had a net margin of 5.43% and a return on equity of 12.41%. Research analysts anticipate that Takeda Pharmaceutical Company Limited will post 2.25 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TAK. BSN Capital Partners Ltd acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter worth about $63,788,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Takeda Pharmaceutical during the second quarter worth about $24,437,000. Goldman Sachs Group Inc. grew its position in Takeda Pharmaceutical by 47.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,732,803 shares of the company’s stock worth $50,878,000 after buying an additional 1,198,284 shares during the period. Van ECK Associates Corp grew its position in Takeda Pharmaceutical by 76.5% during the second quarter. Van ECK Associates Corp now owns 1,989,772 shares of the company’s stock worth $27,936,000 after buying an additional 862,502 shares during the period. Finally, BlackRock Inc. grew its position in Takeda Pharmaceutical by 38.6% during the first quarter. BlackRock Inc. now owns 3,021,274 shares of the company’s stock worth $43,265,000 after buying an additional 842,139 shares during the period. 1.96% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

(Get Rating)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience.

Featured Stories

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.